Evidence map›Paper›PMID 38041698›Full record

ArticlePharmacoEconomics2024

Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force.

Edward Henry, Hareth Al-Janabi, Werner Brouwer, John Cullinan, Lidia Engel, Susan Griffin, Claire Hulme, Pritaporn Kingkaew, Andrew Lloyd, Nalin Payakachat and 7 more

Abstract read
In one paragraph

Article in PharmacoEconomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Cost-effectiveness analysis of the MYO ArmbandJournal of neuroengineering and rehabilitation · 2025
    Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Humanistic and economic burden among caregivers of adults and children with transfusion dependent β-thalassemia: a mixed-methods study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026
    Article
  11. Humanistic and economic burden among caregivers of adults and children with sickle cell disease and recurrent vaso-occlusive crises.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Economic value of non-professional care in Spain. An analysis of the last decade.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  16. Potential of ASCOT-Carer for evaluating the quality of life of family caregivers for patients with Alzheimer's disease in Japan.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026
    Article
  17. Article
  18. Article
  19. Impact of postoperative in-hospital continuous vital sign monitoring on healthcare costs, resource utilization and labor market outcomes.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  20. Measuring health-related quality of life in infants and toddlers: conceptual challenges and proposed recommendations.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Edward HenryJ.E. Cairnes School of Business & Economics, University of Galway, Galway, Ireland. e.henry4@universityofgalway.ie.ORCID 0000-0002-8975-820X
Hareth Al-JanabiHealth Economics Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Werner BrouwerErasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. brouwer@eshpm.eur.nl.
John CullinanJ.E. Cairnes School of Business & Economics, University of Galway, Galway, Ireland.
Lidia EngelMonash University Health Economics Group, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Susan GriffinCentre for Health Economics, University of York, York, UK.
Claire HulmeInstitute of Health Research, University of Exeter Medical School, Exeter, UK.
Pritaporn KingkaewHealth Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand.
Andrew LloydAcaster Lloyd Consulting Ltd, London, UK.
Nalin PayakachatDivision of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Becky PenningtonSchool of Health and Related Research, University of Sheffield, Sheffield, UK.
Luz María Peña-LongobardoFaculty of Law and Social Sciences, University of Castilla-La Mancha, Toledo, Spain.
Lisa A ProsserSusan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
Koonal ShahNational Institute for Health and Care Excellence, London, UK.
Wendy J UngarThe Hospital for Sick Children Research Institute/University of Toronto, Toronto, ON, Canada.
Thomas WilkinsonHealth Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Eve WittenbergHarvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.

Funding

Research BaseP30DK092926 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARY ELLEN MICHELE HEISLER, ADESUWA B OLOMU · 2011 to 2026
$10.0M
Irish Research Council GOIPG/2021/107NIDDK NIH HHS P30 DK092926University of Galway Hardiman Scholarship
6 · The paper itself

Abstract

backgroundOmission of family and caregiver health spillovers from the economic evaluation of healthcare interventions remains common practice. When reported, a high degree of methodological inconsistency in incorporating spillovers has been observed.

aimTo promote emerging good practice, this paper from the Spillovers in Health Economic Evaluation and Research (SHEER) task force aims to provide guidance on the incorporation of family and caregiver health spillovers in cost-effectiveness and cost-utility analysis. SHEER also seeks to inform the basis for a spillover research agenda and future practice.

methodsA modified nominal group technique was used to reach consensus on a set of recommendations, representative of the views of participating subject-matter experts. Through the structured discussions of the group, as well as on the basis of evidence identified during a review process, recommendations were proposed and voted upon, with voting being held over two rounds.

resultsThis report describes 11 consensus recommendations for emerging good practice. SHEER advocates for the incorporation of health spillovers into analyses conducted from a healthcare/health payer perspective, and more generally inclusive perspectives such as a societal perspective. Where possible, spillovers related to displaced/foregone activities should be considered, as should the distributional consequences of inclusion. Time horizons ought to be sufficient to capture all relevant impacts. Currently, the collection of primary spillover data is preferred and clear justification should be provided when using secondary data. Transparency and consistency when reporting on the incorporation of health spillovers are crucial. In addition, given that the evidence base relating to health spillovers remains limited and requires much development, 12 avenues for future research are proposed.

conclusionsConsideration of health spillovers in economic evaluations has been called for by researchers and policymakers alike. Accordingly, it is hoped that the consensus recommendations of SHEER will motivate more widespread incorporation of health spillovers into analyses. The developing nature of spillover research necessitates that this guidance be viewed as an initial roadmap, rather than a strict checklist. Moreover, there is a need for balance between consistency in approach, where valuable in a decision making context, and variation in application, to reflect differing decision maker perspectives and to support innovation.

Indexed as

CaregiversEconomics, MedicalAdvisory CommitteesCost-Benefit AnalysisDelivery of Health CareHumans

Identifiers

PMID38041698
PMCPMC10861630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.